NCT03233711 2026-03-18Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting344 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled
NCT02314169 2025-04-29Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting37 enrolled